BioSpace News Archive

Drug Development

Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies

Codagenix Inc. today announced that their novel intranasal COVI-VAC vaccine has demonstrated promising safety and immunogenicity results in their Phase 1 dose escalation trial in healthy adults.

September 22, 2021
·
3 min read
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19

SAB Biotherapeutics today announced that the U.S. Department of Defense (DoD) has awarded the company an additional $60.5 million in expanded scope for its DiversitAb™ Rapid Response Antibody Program

September 22, 2021
·
10 min read
Drug Development

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

Arcturus Therapeutics Holdings Inc. today announced that it has completed dosing of 100 subjects for the Phase 1 portion of the ARCT-154 Phase 1/2/3 clinical trial, which consisted of a two-dose regimen with injections 28 days apart.

September 22, 2021
·
5 min read
Business

COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax’s CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial

Dynavax Technologies Corporation today announced that Clover Biopharmaceuticals (Clover) reported positive data for their protein-based COVID-19 vaccine candidate, SCB-2019

September 22, 2021
·
6 min read
Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sol-Gel Technologies, Ltd. today announced that the Company will participate in the Cantor Global Healthcare Conference, taking place virtually from September 27th – 30th , 2021.

September 22, 2021
·
1 min read
Biotech Bay

Credence MedSystems Secures $39.9 Million Financing to Enable Scaling of Innovative Drug Delivery and Connected Health Systems

Credence MedSystems, Inc. announced today that it has closed a funding round with gross proceeds of $39.9 million. Sources of funding include strategic investments from Novartis Pharma AG, Molex Ventures LLC as well as additional investors.

September 22, 2021
·
2 min read
Genetown

Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

Inozyme Pharma, Inc. today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, at 1:20 p.m. ET.

September 22, 2021
·
1 min read
Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study

Algernon Pharmaceuticals Inc. is pleased to announce that it has filed a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (U.S. FDA) for its investigation of NP-120 (Ifenprodil) for the treatment of small cell lung cancer (SCLC).

September 22, 2021
·
4 min read
Business

RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions

The Retinal Degeneration Fund announced the launch of Opus Genetics, a patient-focused gene therapy company efficiently developing therapies for orphan inherited retinal diseases.

September 22, 2021
·
5 min read
Pharm Country

ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference

ContraFect Corporation announces that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Cantor Global Virtual Healthcare Conference, which is being held from September 27 – 30, 2021.

September 22, 2021
·
5 min read